Nurix Therapeutics (NASDAQ:NRIX) Posts Earnings Results, Beats Expectations By $5.33 EPS

Nurix Therapeutics (NASDAQ:NRIX) released its earnings results on Monday. The company reported $4.73 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $5.33, Zacks reports. The firm had revenue of $673.06 million for the quarter, compared to analyst estimates of $24.35 million. Nurix Therapeutics had a net margin of 42.01% and a return on equity of 62.20%.

Nurix Therapeutics Stock Down 0.1%

NASDAQ:NRIX opened at $22.13 on Wednesday. The company has a market capitalization of $2.30 billion, a PE ratio of -6.41 and a beta of 1.82. Nurix Therapeutics has a 52-week low of $9.14 and a 52-week high of $28.23. The stock’s 50 day moving average price is $25.17 and its 200 day moving average price is $21.00.

Key Stories Impacting Nurix Therapeutics

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Nurix reported third-quarter 2026 EPS of $4.73, far above the consensus estimate of a $0.56–$0.60 loss, while revenue of $673.1 million substantially exceeded expectations of approximately $24 million. Nurix Therapeutics Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: The company dosed the first patient in the registrational Phase 3 DAYBreak CLL-306 trial, which is comparing bexobrutideg with pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. This advances a key clinical program toward a potential approval opportunity. Nurix Therapeutics Third-Quarter Results and Corporate Update
• Positive Sentiment: RBC Capital Markets said Nurix’s enterprise value remains underappreciated, implying that the firm sees additional value in the company’s pipeline and outlook. Robert W. Baird raised its price target to $36 and maintained an outperform rating, while Needham reaffirmed its buy rating with a $34 target.
• Positive Sentiment: Truist maintained a buy rating and set a $33 price target, despite trimming its prior target from $34.
• Neutral Sentiment: The reported quarter included a very large revenue and EPS beat, but Nurix continues to post deeply negative profitability metrics. Investors may therefore be assessing how much of the quarter’s performance is recurring versus milestone-related or otherwise nonrecurring.

Analyst Ratings Changes

NRIX has been the topic of a number of recent analyst reports. BTIG Research reissued a “buy” rating and issued a $32.00 price objective on shares of Nurix Therapeutics in a research report on Friday, July 10th. UBS Group increased their target price on Nurix Therapeutics from $23.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. Morgan Stanley raised their price target on Nurix Therapeutics from $36.00 to $38.00 and gave the company an “overweight” rating in a research note on Tuesday, July 28th. Needham & Company LLC restated a “buy” rating and issued a $34.00 price target on shares of Nurix Therapeutics in a research note on Tuesday. Finally, Oppenheimer lifted their price target on Nurix Therapeutics from $28.00 to $32.00 and gave the stock an “outperform” rating in a report on Tuesday. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.64.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Hans van Houte sold 4,761 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total transaction of $115,977.96. Following the completion of the sale, the chief financial officer directly owned 40,166 shares of the company’s stock, valued at $978,443.76. This represents a 10.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 1,452 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $25.47, for a total value of $36,982.44. Following the sale, the insider directly owned 117,227 shares of the company’s stock, valued at $2,985,771.69. The trade was a 1.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 21,372 shares of company stock valued at $518,463. 6.70% of the stock is owned by company insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix’s pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton’s tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.